checkAd
    Startseite > Aktien > Ocugen > Nachrichten
    Ocugen Aktie
    1,1510
     
    EUR
    +5,11 %
    +0,0560 EUR
    Letzter Kurs 10:57:58 Tradegate
    1,1130
     
    EUR
    4.000 STK
    Geldkurs 10:35:35
    1,1510
     
    EUR
    4.000 STK
    Briefkurs 10:35:35
    ISIN: US67577C1053 · WKN: A2PSZH · SYM: 2H51 · USA

    Neueste Nachrichten

    Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
    19.04.24 · globenewswire · Ocugen
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
    12.04.24 · Business Wire (engl.) · Ocugen
    Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
    12.04.24 · globenewswire · Ocugen
    EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
    11.04.24 · Business Wire (engl.) · Ocugen
    The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
    10.04.24 · Business Wire (engl.) · Ocugen
    Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
    10.04.24 · globenewswire · Ocugen
    OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
    10.04.24 · Business Wire (engl.) · Ocugen
    Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
    08.04.24 · globenewswire · Ocugen
    Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
    05.04.24 · globenewswire · Ocugen
    Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
    02.04.24 · globenewswire · Ocugen
    Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
    02.04.24 · globenewswire · Ocugen
    Ocugen to Host Conference Call on Tuesday, April 2 at 8: 30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
    01.04.24 · globenewswire · Ocugen